Relacorilant - Corcept Therapeutics

Drug Profile

Relacorilant - Corcept Therapeutics

Alternative Names: CORT-125134

Latest Information Update: 20 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Corcept Therapeutics
  • Developer Corcept Therapeutics; Johns Hopkins University; National Institute on Alcohol Abuse and Alcoholism
  • Class Small molecules
  • Mechanism of Action Glucocorticoid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cushing syndrome
  • Phase I/II Solid tumours
  • Clinical Phase Unknown Alcoholism

Most Recent Events

  • 20 Nov 2017 Chemical structure information added
  • 08 Nov 2017 CORT 125134 is now called relacorilant
  • 02 Nov 2017 Corcept Therapeutics plans a phase III trial in Cushing's syndrome in the third quarter of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top